Melissa Epperly - Feb 1, 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Financial Officer
Signature: By: /s/ Melissa B. Epperly
Stock symbol: ZNTL
Transactions as of: Feb 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/1/2023, 06:07 PM
Previous filing: Oct 3, 2022
Next filing: Feb 14, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+102K	+34.22%	$0.00	400K	Feb 1, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+148K		$0.00	148K	Feb 1, 2023	Common Stock	148K	$23.65	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2	Includes 399 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2022.
F3	The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.